 |
Niatab 500 by Douglas Labs 100 Tablets
Supports Cardiovascular And Cholesterol Health*
| Our Price: $9.90 | 
|
Niatab 500 tablets, provided by Douglas Laboratories, slowly release 500 mg of pure niacin over a 2 to 3.5 hour period to reduce the skin-flushing effect that niacin sometimes has. Niacin regulates fundamentally important physiological functions within the body. Without it, the body cannot release energy from carbohydrates or fats that are consumed.* In addition, studies have shown that it is helpful in the healthy metabolism of cholesterol.* Sustained release niacin is better tolerated than regular crystalline high-potency niacin supplements. Niatab 500 is a scored uncoated tablet which can be broken in half when lower dosage is desired. FUNCTIONS Niacin (vitamin B-3) occurs in the body as two metabolically active coenzymes, NAD (nicotinamide adenine dinucleotide) and NADP (NAD phosphate). The niacin coenzymes NAD and NADP have pervasive roles in energy-related and biosynthetic metabolic processes.* At least 200 enzymes depend on these niacin cofactors. The NAD-dependent enzymes are involved in mostly catabolic, oxidative reactions that release energy from carbohydrate, fat, and protein, whereas the NADP-dependent enzymes more commonly function in biosynthetic pathways of such compounds as fatty acids and steroid hormones.* Independent of its functions as NAD or NADP, niacin is also involved in the regulation of normal blood lipoprotein and cholesterol levels. Dietary niacin is generally well absorbed and taken up by the liver which converts it to NAD and NADP. Any excess niacin is metabolized by the liver and excreted by the kidneys.* Because the liver has a limited capacity to metabolize niacin, high doses of regular, crystalline niacin are often not well tolerated, causing vasodilatory side effects known as skin-flushing and itching. For maximum benefit and fewer side effects, Niatab 500 releases its niacin over a time frame of two to three hours. This way, the niacin is more efficiently utilized by the liver and more evenly distributed to peripheral tissues compared to crystalline niacin. For the same reasons, Niatab 500 can generally be used at somewhat lower doses than crystalline niacin supplements.* INDICATIONS Niatab 500 tablets may be a useful nutritional adjunct for individuals who wish to increase their intake of niacin without the uncomfortable side effects of skin flushing.
|
|
Supplement FactsServing Size: One (1) Scored Tablet Servings Per Container: 100 | | | | Amount Per Serving | Daily Value | | Niacin | 500 mg | 2,500% | | ** Daily Value Not Established. Percent Daily Values are based on a 2,000 calorie diet. |
|
 |
|
| Cellulose, Magnesium Stearate, Silicon Dioxide, Vegetable Sterine |
 |
| As a dietary supplement, one-half to one (½ - 1) tablet, one to two (1 - 2) times daily during or after a meal, or more as directed by physician. ... As a general guideline when substituting Niatab 500 for crystalline niacin, use Niatab 500 at 1/2 to 2/3 of the level used for crystalline niacin. |
 |
| Keep out of the reach of children ... Store in a cool, dry place ... Do not use if outer seal is missing. |
 |
| No adverse effects have been reported. |
 |
|
| Cardiovascular Health, Cholesterol Health |
 |
| Cardiovascular |
 |
Alderman JD et al. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol 1989;64:725-729. Canner PL et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255. Colletti RB et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993;92:78-82. Keenan JM et al. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 1991;151:1424-1432. Lavie CJ et al. Marked benefit with sustained-release niacin therapy in patients with ‘isolated’ very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992;69:1083-1085. Probstfield JL. Nicotinic acid as a lipoprotein-altering agent: therapy directed by the primary physician. Arch Int Med 1994;154:1557-1559. |
 |
| ProductData |
 |
Our Price: $9.90 |

|
|
|
|